



**ASX Announcement | 8 September 2020**  
**Noxopharm Limited (ASX:NOX)**

## **Global CRO To Execute DARRT-2 Prostate Cancer Study**

**Sydney 8 September 2020: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX)** is pleased to announce that after a rigorous global search, the clinical research organisation (CRO), Parexel® Biotech, has been appointed to manage the Company's Phase 2 DARRT-2 clinical study.

This marks a major commitment by the Company in its aim of seeing Veyonda® eventually come to market as a final line of treatment of end-stage cancer, with the DARRT program focused on prostate cancer in the first instance.

The clinical objective with Veyonda® is to deliver a form of immuno-oncology therapy considerably better tolerated, more accessible, more cost-effective and more broadly active than current forms of immuno-oncology therapy.

DARRT (Direct and Abscopal Response to RadioTherapy) is a novel form of immuno-oncology based on the ability of Veyonda® to convert tumours from COLD (lacking immune function) to HOT (possessing immune function). DARRT relies on a low dose of radiotherapy to provide the trigger for immune activation, with the role of Veyonda® being to amplify and spread that response to tumours throughout the body.

The DARRT-2 study is a multi-national Phase 2 control-arm study in approximately 200 men with end-stage metastatic castrate-resistant prostate cancer.

Hospital and clinician recruitment will now commence, with all regulatory and ethical approvals to follow. Patient recruitment is anticipated to commence early in the New Year. The trial has a number of in-built milestones that will be reported on over the course of the study.

What the Company is hoping to show is that a combination of Veyonda® and low-dose radiotherapy delivered as standard external beam radiotherapy is well tolerated and provides a more meaningful anti-cancer response (less disease progression, less pain, better quality of life) compared to standard palliative care.

Parexel Biotech will administer and implement the study. Parexel Biotech is a division of Parexel, a global leader in biopharmaceutical and CRO services. With more than 20,000 employees in 100 countries around the world, Parexel Biotech is ideally situated to commence the administration and implementation of the DARRT-2 study.

*Graham Kelly, CEO and Executive Chairman of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.*



**-ENDS-**

**About Noxopharm**

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – inhibition of sphingosine kinase and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking sepsis.

Noxopharm also is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR).

To learn more, please visit: [noxopharm.com](http://noxopharm.com)

**Investor & Corporate enquiries:**

Prue Kelly  
M: 0459 022 445  
E: [info@noxopharm.com](mailto:info@noxopharm.com)

**Company Secretary:**

David Franks  
T: +61 2 8072 1400  
E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

**Media Enquiries**

Julia Maguire  
The Capital Network  
E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)  
T: + 61 2 8999 3699

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.